Kura Oncology (KURA) Stock Overview
A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
KURA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Kura Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.34 |
| 52 Week High | US$21.57 |
| 52 Week Low | US$5.41 |
| Beta | 0.40 |
| 1 Month Change | 15.05% |
| 3 Month Change | 21.93% |
| 1 Year Change | -61.87% |
| 3 Year Change | -51.93% |
| 5 Year Change | -65.57% |
| Change since IPO | -51.07% |
Recent News & Updates
Health Check: How Prudently Does Kura Oncology (NASDAQ:KURA) Use Debt?
Jul 14
Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well
Jul 02Recent updates
Health Check: How Prudently Does Kura Oncology (NASDAQ:KURA) Use Debt?
Jul 14Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well
Jul 02Analysts Just Shipped A Captivating Upgrade To Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates
May 07Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Boosting Their Estimates
May 04
NDA Submission And Trial Progress Will Forge Market Opportunities
Successful NDA submission and accelerated approval paths could enable early market entry, boosting future revenues and earnings.Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity
Mar 04Industry Analysts Just Upgraded Their Kura Oncology, Inc. (NASDAQ:KURA) Revenue Forecasts By 62%
Mar 04Kura Oncology: Sentiment Is Too Negative
Jan 23Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Dec 18Kura Oncology: A Contender In The Field Of Precision Medicine
Nov 21Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?
Nov 01Kura Oncology: The Long Holding Pattern Is Risky
Aug 12Estimating The Fair Value Of Kura Oncology, Inc. (NASDAQ:KURA)
Jul 12Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
May 08Kura Oncology: Balancing Act Of Promise And Pragmatism
May 07Kura Oncology: Ziftomenib's Path To AML Market Widens
Jan 31Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price
Jan 25Is Kura Oncology (NASDAQ:KURA) A Risky Investment?
Aug 14Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
Apr 04Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?
Jan 31Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans
Oct 10Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating
Jul 13We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth
Jun 26We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Nov 23We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Aug 09Shareholder Returns
| KURA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 32.5% | 4.5% | 1.0% |
| 1Y | -61.9% | -5.1% | 17.1% |
Return vs Industry: KURA underperformed the US Biotechs industry which returned -6.5% over the past year.
Return vs Market: KURA underperformed the US Market which returned 17.4% over the past year.
Price Volatility
| KURA volatility | |
|---|---|
| KURA Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KURA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KURA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 192 | Troy Wilson | kuraoncology.com |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd.
Kura Oncology, Inc. Fundamentals Summary
| KURA fundamental statistics | |
|---|---|
| Market cap | US$572.86m |
| Earnings (TTM) | -US$197.17m |
| Revenue (TTM) | US$83.28m |
Is KURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KURA income statement (TTM) | |
|---|---|
| Revenue | US$83.28m |
| Cost of Revenue | US$198.11m |
| Gross Profit | -US$114.83m |
| Other Expenses | US$82.34m |
| Earnings | -US$197.17m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.27 |
| Gross Margin | -137.89% |
| Net Profit Margin | -236.76% |
| Debt/Equity Ratio | 3.1% |
How did KURA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/15 19:29 |
| End of Day Share Price | 2025/08/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kura Oncology, Inc. is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Jason Zemansky | BofA Global Research |
| Leah Rush Cann | Brookline Capital Markets |